Drug Shortages And Biosimilars

Historical Context & Motivation

The phenomenon of drug shortages has been a persistent and escalating challenge in the United States healthcare system for over two decades. Although sporadic shortages occurred before the turn of the millennium, the problem intensified dramatically in the late 2000s when critical medications—including injectable oncology agents, anesthetics, and basic electrolyte solutions—became unavailable for extended periods. Pharmacists found themselves on the front lines, tasked with identifying therapeutic alternatives, communicating with prescribers, and rationing limited supplies. The concurrent emergence of biosimilars—highly similar versions of approved biologic reference products—offered a promising mechanism to expand the supply chain, reduce costs, and mitigate shortages of expensive biologic therapies. Together, drug shortages and biosimilars represent two deeply interconnected pillars of the modern medication use process that every pharmacist must understand.

The critical question that unites these two topics is straightforward yet complex: how can the healthcare system ensure that patients have reliable, timely access to safe and effective medications? Understanding the root causes of drug shortages, the regulatory frameworks governing biosimilar approval, and the pharmacist's role in managing both challenges is essential for NAPLEX preparation and clinical practice alike.

Core Principles & Definitions

Before exploring the details of shortage management and biosimilar regulation, it is essential to establish foundational definitions and principles. A drug shortage is defined by the FDA as a period of time when the demand or projected demand for a medically necessary drug in the United States exceeds the supply of the drug. A biologic product is a large, complex molecule derived from living cells or organisms—examples include monoclonal antibodies, cytokines, and hormones such as insulin. A biosimilar is a biologic product that is highly similar to an already-approved reference product with no clinically meaningful differences in terms of safety, purity, and potency. An interchangeable biosimilar meets additional criteria demonstrating that it can be expected to produce the same clinical result as the reference product in any given patient, including during alternating or switching.

Visual Explanation — Drug Shortage Lifecycle

As illustrated in the diagram, the shortage lifecycle begins with a triggering event—most commonly a manufacturing quality issue that accounts for roughly 62% of all shortages. These disruptions may involve contamination events, equipment failures, or FDA warning letters leading to production halts. Once a shortage is detected—typically through manufacturer notification to the FDA as required by the FDA Safety and Innovation Act (FDASIA) of 2012—the severity is assessed and both institutional and federal responses are mobilized. Pharmacists play a critical role at the management stage, employing therapeutic substitution, dose optimization, and allocation protocols to preserve supply for the most critical patients.

How Biosimilar Approval Works — The 351(k) Pathway

Unlike small-molecule generics approved under the Abbreviated New Drug Application (ANDA) pathway (Section 505(j) of the FD&C Act), biosimilars are approved under Section 351(k) of the Public Health Service Act. This pathway was created by the BPCIA because biologics cannot be shown to be 'identical' in the same way that generic drugs demonstrate pharmaceutical equivalence through bioequivalence testing. Biologics are produced by living systems, and even minor changes in manufacturing conditions can alter the molecule's structure. The 351(k) pathway therefore requires a stepwise, totality-of-the-evidence approach to demonstrate biosimilarity rather than identity.

Stepwise Totality-of-the-Evidence Framework

The FDA evaluates biosimilar applications through a hierarchical framework that proceeds from the most sensitive analytical comparisons to clinical data. At the base are analytical studies comparing the proposed biosimilar to the reference product, assessing primary structure, higher-order structure, post-translational modifications, biological activity, and receptor binding kinetics. Next, nonclinical studies (animal pharmacokinetic and toxicology studies) may be required if residual uncertainty remains. Finally, clinical studies including pharmacokinetic (PK) and pharmacodynamic (PD) comparisons in healthy volunteers or sensitive patient populations, and possibly a comparative clinical efficacy and safety trial, are conducted to resolve any remaining differences. The principle of this inverted pyramid is that robust analytical characterization can reduce the need for extensive clinical trials.

Extrapolation of Indications

A powerful aspect of the biosimilar pathway is the concept of extrapolation. If a biosimilar demonstrates similarity in one clinical indication, the FDA may approve it for all indications of the reference product for which biosimilarity has been scientifically justified. For example, a biosimilar to rituximab may be studied only in rheumatoid arthritis but be approved for all of rituximab's oncology and autoimmune indications, provided that the mechanism of action and receptor interactions are consistent across conditions. This principle significantly reduces the cost and time of development.

Classification of Shortages & Key Biosimilar Categories

Drug Shortage Categories by Therapeutic Area

Drug shortages disproportionately affect certain therapeutic categories. Sterile injectable products—including chemotherapy agents, antibiotics, anesthetic agents, and parenteral nutrition components—constitute the majority of active shortages because their manufacturing is technically demanding, requires aseptic processing, and is concentrated among a small number of manufacturers. When one facility encounters quality problems, the entire market may be disrupted. Understanding which drug classes are most vulnerable helps pharmacists anticipate and prepare for shortages.

Key Biosimilar Categories in the U.S. Market

Worked Example — Managing a Drug Shortage Scenario

The following worked example demonstrates how a pharmacist might systematically approach a drug shortage affecting patient care, incorporating both shortage management principles and biosimilar considerations.

Biosimilars vs. Generics — Key Distinctions

One of the most common sources of confusion among students and clinicians alike is the distinction between a generic drug and a biosimilar product. While both seek to provide lower-cost alternatives to branded medications after exclusivity periods expire, the scientific, regulatory, and clinical frameworks differ substantially. Understanding these differences is essential for pharmacists who make formulary decisions and counsel patients and providers about these products.

Regulatory Landscape & Future Directions

The regulatory and policy landscape surrounding drug shortages and biosimilars continues to evolve rapidly. The pharmacist's role is expanding from reactive shortage management to proactive supply chain resilience planning, and from passive biosimilar dispensing to active stewardship of biologic utilization. Understanding the current regulatory framework and emerging trends prepares pharmacists for the shifting landscape of the medication use process.

Practice Problems

Lesson Summary